NCT00246935已完成3 期
A Long-term Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Long-term safety after 28 weeks treatment of Roflumilast (total 52 weeks, 24 weeks of study APTA-2217-06 followed by 28 weeks) .
研究概览
简要总结
The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with chronic obstructive pulmonary disease (COPD) who completed the 24-week evaluation of study APTA-2217-06. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is an extension of the 24-week study APTA-2217-06 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Long-term safety after 28 weeks treatment of Roflumilast (total 52 weeks, 24 weeks of study APTA-2217-06 followed by 28 weeks) .
次要结局
- Efficacy.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).Bronchial AsthmaNCT00246922AstraZeneca150
已完成
2 期
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)Chronic Obstructive Pulmonary Disease (COPD)NCT00242294AstraZeneca570
已完成
2 期
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05).Bronchial AsthmaNCT00242307AstraZeneca450
已完成
2 期
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs SchizophreniaSchizophreniaNCT01626885Tanabe Pharma Corporation42
已完成
2 期
Long-Term Study of MP-214 in Patients With SchizophreniaSchizophreniaNCT01626872Tanabe Pharma Corporation254